Strategic positioning Purisys-Siegfried collaboration positions the company as a global CDMO with capabilities in cannabinoids, psychedelics, reference standards, and complex HPAPI development, presenting opportunities to upsell integrated API development, cGMP manufacturing, and niche clinical-to-commercial programs.

Expansion signals Recent facility expansion in Minden, Germany and ongoing growth indicate capacity for larger-scale drug substance production, enabling sales pitches for scale-up, late-stage manufacturing, and supply chain resilience for pharma and biotech partners.

Regulatory readiness Existing GMP manufacturing suites, multiple DMFs for cannabinoids, and DEA licenses for psychedelic classes suggest strong regulatory route readiness, enabling a value proposition around compliant supply for IND/IMPD/NDA/ANDA filings and new program introductions.

Technical leadership Capabilities in HPAPI and labile molecule development, method development, excipient compatibility, and in-stock reference standards create cross-sell opportunities for customers needing end-to-end support from early API discovery to polished regulatory-ready filings.

Reference standards ecosystem With a catalog of 250+ reference standards shipped globally, there is potential to bundle standard procurement with custom synthesis programs, offering bundled analytical support and faster time-to-study for pharma and biotech customers.